Market Overview

UPDATE: Canaccord Genuity Downgrades Tranzyme to Hold, Lowers PT

Related TZYM
Tranzyme, Ocera Announce Merger Agreement
A Peek Into The Market Before The Trading Starts

In a report published Friday, Canaccord Genuity downgraded its rating on Tranzyme (NASDAQ: TZYM) from Buy to Hold, and lowered its price target from $7 to $1.50.

Canaccord Genuity noted, “Lowering to HOLD, decreasing target to $1.50 on lowered probability of TZP-102 success in diabetic gastroparesis. Our valuation is driven by the TZP-102 for gastroparesis, and after this Ph2b trial miss, we lower our probability of success to 10% from 40%. Our pNPV-derived target of $1.50 is based on TZP-102's chances of clinical and regulatory success.”

Tranzyme closed on Thursday at $0.95.

Latest Ratings for TZYM

DateFirmActionFromTo
Nov 2012CanaccordDowngradesBuyHold
Nov 2012BMO Capital MarketsDowngradesOutperformMarket Perform
Aug 2012CanaccordUpgradesHoldBuy

View More Analyst Ratings for TZYM
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Downgrades Analyst Ratings

 

Related Articles (TZYM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters